WHO wants vaccine efficacy data in monkeypox fight
In this file handout photo taken on June 22, 2022 made available by the UK Health Security Agency shows a collage of monkeypox rash lesions at an undisclosed date and location. (Photo: AFP)

GENEVA, Switzerland (AFP) — The World Health Organization on Wednesday appealed for vigilance to ensure monkeypox does not spread among more vulnerable groups, such as children.

Fighting the virus required "intense" efforts, said the WHO, calling for broad data collection and sharing on how well vaccines work against it.

Experts have detected a surge of monkeypox cases since early May outside of the West and Central African countries where the disease has long been endemic. Most of the new cases have been in western Europe.

"I am concerned about sustained transmission because it would suggest that the virus is establishing itself and it could move into high-risk groups including children, the immunocompromised and pregnant women," WHO chief Tedros Adhanom Ghebreyesus told reporters.

"We are starting to see this, with several children already infected."

There are two cases aged under 18 in Britain.

WHO chief scientist Soumya Swaminathan called for "very careful studies of the vaccine in different population groups ... so that we get data that's broadly applicable, and also to ensure that children, pregnant women and the immunosuppressed are considered for inclusion in these trials".

As of June 22 this year, 3,413 laboratory-confirmed cases and one death have been reported to the WHO, from 50 countries.

WHO emergencies director Michael Ryan said that countries with stockpiles of vaccines, led by the United States, had shown willingness to share them.

However, they had largely only been licensed for use against monkeypox's far more severe relative smallpox, which is also caused by an orthopoxvirus and which is the only disease successfully eradicated through vaccination.

"It's really important as we encourage the sharing of these products that we also collect the necessary clinical efficacy data," said Ryan.

Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at https://bit.ly/epaper-login


  1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper; email addresses will not be published.
  2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.
  3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.
  4. Please do not write in block capitals since this makes your comment hard to read.
  5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed: advertising@jamaicaobserver.com.
  6. If readers wish to report offensive comments, suggest a correction or share a story then please email: community@jamaicaobserver.com.
  7. Lastly, read our Terms and Conditions and Privacy Policy